Celsion (CLSN -11.4%) sinks again today after noting in a SEC filing that it's entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell $25M worth of shares, from time to time. The stock cratered last week on news that its liver cancer drug TheromDox had failed its latest clinical trials.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs